Highlights from

EHA 2019

European Hematology Association

Amsterdam 13-16 June 2019

Editor Biography

Professor Gert Ossenkoppele was appointed in 2003 as professor of Hematology at the VU University Medical Center in Amsterdam. Gert Ossenkoppele has authored over 390 publications in peer-reviewed journals and is an invited speaker at many international scientific meetings. His research interests are mainly translational and include the (stem cell) biology of AML, leukemic stem cell target discovery, immunotherapy, and measurable residual disease (MRD) detection using flow cytometry to inform treatment of AML. He is the PI of various clinical trials in myeloid malignancies. He chairs the AML working party of HOVON (Dutch-Belgian Hematology Trial Group) and is appointed as vice-chair of the HOVON Executive Board. He is a lead participant of the AML Work package of the European LeukemiaNet (ELN) as well as a board member of the ELN foundation. He is recently appointed as chair of the EHA Educational Committee. He chairs the AML Scientific working group of EHA, and he is chair of the Global and EU steering committee of the AMLGlobalPortal an educational portal for hematologists (www.amlglobalportal.com).

Conflict of Interest Statement: Prof. Ossenkoppele is consultant for Novartis and BMS.

Article image: Medicom

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.